News & Media: All

Jan 12, 2018

PHE Expert Shafrin: Make Real-World Evidence the New Gold Standard

In an in-depth commentary for Pharmaceutical Market Europe, PHE senior economist Jason Shafrin argues for real-world evidence (RWE) to become the "gold standard" of scientific evidence and heath technology assessments.RWE provides an opportunity to accelerate drug approval, monitor treatment saf ...

Dec 14, 2017

Precision’s Snider Interviewed by AJMC Regarding New CAR-T Societal Value Study

A new Precision Health Economics-authored study on the societal value of CAR-T therapy is generating a significant level of interest within the scientific community. PHE’s Julia Snider touches on some of the key takeaways of the study, presented at this year’s ASH, with the American Journa ...

Dec 5, 2017

New PHE Study Released on Cost of Nonadherence

A novel approach to measuring the cost of nonadherence is outlined in a new article by Precision experts Jason Shafrin, Ross Maclean, and colleagues. The authors report findings of an adherence-exposure-outcome model simulation on the impact of nonadherence on progression-free survival in Cancer ...

Nov 9, 2017

Precision's Shafrin Writes of the Value of Real-World Evidence in Drug Discovery & Development

In a new article for Drug Discovery & Development, Precision Health Economics senior research economist Jason Shafrin addresses the use of real-world evidence, why we need it and how to effectively implement it.

To read the complete article, please click here.

Nov 8, 2017

POLITICO Pulses on Launch of IVI's New Open-Source Value Tool

Must-read morning briefing POLITICO Pulse talks with Innovation & Value Initiative (IVI) executive director Darius Lakdawalla on the launch of a first-of-its-kind open-source project for determining the value of medical treatments. IVI, a Precision Health Economics-backed collaboration, is debut ...

Nov, 2017

Precision's Maclean Sits Down With Conquer to Talk Personalized Medicine

Precision Health Economics Head of Medical, Dr. Ross Maclean, participates in a Q&A with patient advocate forum Conquer discussing the importance of personalized medicine. Maclean explains the 3 critical elements of personalized medicine and how personalized medicine differs from other types of ...

Oct 27, 2017

PHE Webinar: Beyond Traditional Cost-Effectiveness Analysis: The Importance of Novel Value Components

This unique webinar addresses current standards of cost-effectiveness analysis- including limitations and challenges- and reviews often overlooked sources of value and the importance of these alternative value assessments in discussions with payers, policymakers, and other stakeholders.

(w/Q&A s ...

Sep 27, 2017

PHE at ISPOR Europe – November 4th through 8th – Glasgow, Scotland

Precision Health Economics will be well represented at ISPOR’s 20th Annual European Congress, to be held November 4-8 at the Scottish Events Campus, Glasgow, Scotland.

In addition to the numerous PHE-led short courses, issue panels, podium presentations, breakout sessions, workshops and pos ...

Sep, 2017

PHE's Goldman in Fortune: Innovative Drugs Deserve Innovative Pricing

PHE cofounder Dana Goldman, along with coauthor David Agus, contribute a new commentary for Fortune.com. Discussing the significance of Kymriah, the first gene therapy for cancer to achieve FDA approval, Goldman and Agus make the point that altough the promise and pricing of the new drug is grab ...

Aug 25, 2017

PHE’s Shafrin Defines Precision Medicine for US News & World Report

In a new commentary for US News & World Report, Precision Health Economics’ senior research economist Jason Shafrin defines and elaborates on the field of precision medicine. Jason, also director of research for the Precision for Medicine-initiated Innovation and Value Initiative (thevalueini ...

Jul 24, 2017

PHE Researchers Publish New Study Comparing Clinical Trial Efficacy and Real-World Effectiveness for Cancer Therapies

A new study by PHE researchers recently published in Value in Health, the official journal of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), examines the relationship between the efficacy of randomized controlled trials (RCTs) and real-world effectiveness for onco ...

Jul 21, 2017

Managed Healthcare Connect Presents Details of New PHE RA Study

Christina Vogt with Managed Healthcare Connect recently provided a breakdown and analysis of a new PHE study on the impact of ACPA status on patient costs associated with rheumatoid arthritis.

Published in the Journal of Managed Care Pharmacy, the study demonstrated that patients with rheum ...

Jul 21, 2017

Jena Discusses New PHE Preeclampsia Study with Orlando Sentinel

PHE Scientific Advisor Anupam Jena, coauthor of a new study on preeclampsia in the September issue of American Journal of Obstetrics & Gynecology, discussed the study’s findings and the growing economic impact of the condition with the Orlando Sentinel’s Amelia Cheatham.

The study by Jena ...

Jul 17, 2017

Study by Precision’s Sharma Named as One of Five Most Influential Articles of 2016

Precision would like to congratulate Abhishek Sharma, Associate Health Economist, Evidence Strategy & Generation, for his outstanding work as coauthor of an article appearing in the Journal of Pharmaceutical Policy and Practice, named one of their five most influential articles of 2016.

The fi ...

Jun 20, 2017

Precision’s Goldman and Lakdawalla in WSJ: Look to Major League Baseball for Drug Pricing Insight

In a new commentary appearing in The Wall Street Journal, Precision Health Economics cofounders Dana Goldman and Darius Lakdawalla turn to the national pastime to provide a fresh perspective on the issue of drug pricing and the return on investment pharmaceutical companies need to sustain innova ...

Jun 19, 2017

Maclean Talks Payer Access and New Opportunities Arising From Cures 3037

During the recent ISPOR conference, Ross Maclean, Precision Health Economics' SVP, Head of Medical, sat down to talk with Med Ad News’ Christiane Truelove on new opportunities for payer access in light of new FDA draft guidance around section 3037 of the 21st Century Cures Act. While Maclean ...

Jun 9, 2017

Jason Shafrin's Blog Named to Top 100 Economics Blogs of 2017 List

For the second year in a row, Precision Health Economics Senior Research Economist Jason Shafrin’s blog, “Healthcare Economist,” has been named by Intelligent Economist to their list of Top 100 Economics Blogs (worldwide). Jason’s blog is listed first in the economic blogs category, ...

Jun 8, 2017

Goldman and Jena Discuss the Challenges of Value-Based Pricing in STAT News

In a new commentary for STAT News, PHE co-founder Dana Goldman and scientific advisor Anupam Jena discuss the advantages of value-based pricing, pointing out several of the key challenges that complicate the application of health technology assessments. Goldman and Jena make the case that more t ...

Jun 2, 2017

PHE's Lakdawalla in LA Times: Providing Perspective on California's Proposed Single-Payer Plan

PHE Co-founder and Chief Scientific Officer Darius Lakdawalla speaks with Melanie Mason from The Los Angeles Times in a new Q&A, discussing the implications of California's new legislation favoring a single-payer healthcare system.

To read the complete article, please click here.

Jun, 2017

Schafer, Galante, and Shafrin in JMCP: New Precision Survey Provides Insight Into Payer Use of Value Tools

In the current supplemental issue of Journal of Managed Care & Specialty Pharmacy (JMCP), Precision’s Jeremy Schafer, Dominic Galante, and Jason Shafrin share results of a recent survey of payers discerning payers’ use of value tools in healthcare decision-making.

Deploying Precision for ...

May 23, 2017

PHE's Baumgardner Participates in Becker Friedman Institute Health Care Reform Panel

On May 22nd, PHE Senior Research Economist James Baumgardner was an invited panelist for The University of Chicago's Becker Friedman Institute for Research in Economics. On the panel, titled "The Economic Consequences of Health Care Reform," James applied his past experience as a 20-year veteran ...

May 19, 2017

Precision’s Abhishek Sharma Selected for World Heart Federation’s Emerging Leaders Program

Congratulations to Associate Health Economist Abhishek Sharma, part of Precision Health Economics’s Evidence Strategy, Generation, and Communications team, for his acceptance into the World Heart Federation’s Emerging Leaders (EL) program. The program is part of a WHF initiative to reduce ...